Raymond James raised the firm’s price target on ARS Pharmaceuticals (SPRY) to $28 from $26 and keeps a Strong Buy rating on the shares. ARS Pharmaceuticals pre-announced Q4 net sales of $6.5M ...

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

It's been a wild year in tech thanks to the intersection between humans and artificial intelligence. 2024 brought a parade of AI oddities, mishaps, and wacky moments that inspired odd behavior ...

“For ARS Pharma, 2024 marked a pivotal year, securing regulatory approvals for neffy as the first and only intranasal epinephrine treatment, laying a solid foundation for our commercial success ...